マーケットレポート詳細

モノクローナル抗体医薬品市場:2029年に至る製造法別、治療分野別予測

Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029

出版元:MarketsandMarkets   出版元について
発行年:2024年3月
定価 :Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文351ページになります。
商品コード:MAM3569

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

モノクローナル抗体医薬品の世界市場規模は2024年で2526億ドル、2029年に4975億ドル、市場の平均年成長率は14.5%にて増加すると見込まれています。

レポートはモノクローナル抗体の世界市場について2029年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測(製造方法別、市場、投与経路別市場、等)を中心に構成されています。また競合状況、主要企業情報(15社)、バリューチェーン分析、特許分析なども加味し、モノクローナル抗体医薬品市場の動向および今後成長性を詳細にレポートしています。

【レポート構成概要】

◆モノクローナル抗体医薬品市場の世界市場予測2022-2029年

・市場規模(US$)

◆製造方法別、市場-2029年

・試験管内生産 (In Vitro)
・生体内生産 (In Vivo)
※(市場規模US$) 

◆投与経路別、市場-2029年

・静脈内投与
・皮下投与経路
・その他投与経路
※(市場規模US$) 

◆由来原料別、市場-2029年

・ヒューマンソース
・ヒューマナイズドソース
・キメラソース
・その他由来原料
※(市場規模US$) 

◆治療エリア別、市場-2029年

・炎症性/自己免疫疾患
・腫瘍
・血液内科
・眼科
・その他治療エリア
※(市場規模US$) 

◆エンドユーザー別、市場-2029年

・病院
・長期療養施設
・その他エンドユーザー
※(市場規模US$) 

◆主要国地域別市場-2029年

北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン、トルコ
・その他欧州
アジア太平洋
・日本、中国、インド
・韓国、インドネシア、マレーシア
・その他アジア太平洋
中南米
・ブラジル
・その他中南米
中東
・GCC諸国
-サウジアラビア
-アラブ首長国連邦
-その他GCC諸国
・その他中東
アフリカ
※地域、国別に、全セグメント別の細分化データ掲載、詳細は目次参照

◆市場分析

・市場ダイナミクス
・ファイブフォース分析
・技術分析
・バリューチェーン分析
・特許分析
・サプライチェーン分析
・エコシステム分析
・規制状況
・平均価格分析
・主要なステークホルダーと購買基準
・競合状況
・市場シェア分析

◆モノクローナル抗体医薬品市場の主要企業プロフィール動向

・F HOFFMANN-LA ROCHE LTD
・JOHNSON & JOHNSON SERVICES, INC
・MERCK & CO, INC
・ABBVIE INC
・BRISTOL-MYERS SQUIBB COMPANY
・ASTRAZENECA
・SANOFI
・NOVARTIS AG
・AMGEN INC
・武田薬品工業株式会社
・GSK PLC
・ELI LILLY AND COMPANY
・REGENERON PHARMACEUTICALS INC
・BIOGEN
・UCB SA

その他企業
・BOEHRINGER INGELHEIM INTERNATIONAL GMBH
・Y-MABS THERAPEUTICS, INC
・TEVA PHARMACEUTICAL INDUSTRIES LTD
・MERCK KGAA
・協和キリン株式会社
・SWEDISH ORPHAN BIOVITRUM AB
・UNITED THERAPEUTICS CORPORATION
・THERATECHNOLOGIES INC
・INCYTE
・SUN PHARMACEUTICAL INDUSTRIES, INC

(全351頁)
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次)

1     INTRODUCTION

1.1          STUDY OBJECTIVES
1.2          MARKET DEFINITION
1.2.1           INCLUSIONS & EXCLUSIONS   29
1.3          MARKET SCOPE
1.3.1           MARKETS COVERED
1.3.2           YEARS CONSIDERED
1.3.3           CURRENCY CONSIDERED
1.4          RESEARCH LIMITATIONS
1.5          STAKEHOLDERS
1.6          RECESSION IMPACT

2     RESEARCH METHODOLOGY

2.1          RESEARCH DATA
・     FIGURE 1          RESEARCH DESIGN
2.1.1           SECONDARY DATA
2.1.2           PRIMARY DATA
・     FIGURE 2          MONOCLONAL ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
2.2          MARKET SIZE ESTIMATION
・     FIGURE 3          MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023
・     FIGURE 4          MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (PRODUCT-BASED ANALYSIS), 2023
・     FIGURE 5          MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
・     FIGURE 6          ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE AG: REVENUE SHARE ANALYSIS, 2023
2.2.1           INSIGHTS FROM PRIMARIES
・     FIGURE 7          MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2           SEGMENT ASSESSMENT (BY PRODUCTION METHOD, SOURCE, ROUTE OF ADMINISTRATION, THERAPY AREA, AND END USER)
・     FIGURE 8          MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3          GROWTH RATE ASSUMPTIONS
・     FIGURE 9          MONOCLONAL ANTIBODY THERAPEUTICS MARKET: CAGR PROJECTIONS, 2024–2029
・     FIGURE 10        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4          MARKET BREAKDOWN AND DATA TRIANGULATION
・     FIGURE 11        DATA TRIANGULATION METHODOLOGY
2.5          STUDY ASSUMPTIONS
2.6          RISK ANALYSIS
2.7          RECESSION IMPACT ANALYSIS

3     EXECUTIVE SUMMARY

・     FIGURE 12        MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2024 VS. 2029 (USD MILLION)
・     FIGURE 13        MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
・     FIGURE 14        MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY TYPE, 2024 VS. 2029 (USD MILLION)
・     FIGURE 15        MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
・     FIGURE 16        GEOGRAPHICAL SNAPSHOT OF MONOCLONAL ANTIBODY THERAPEUTICS MARKET

4     PREMIUM INSIGHTS

4.1          MONOCLONAL ANTIBODY THERAPEUTICS MARKET OVERVIEW
・     FIGURE 17        ADVANCEMENTS IN BIOTECHNOLOGY AND GENETIC ENGINEERING TO DRIVE MARKET DURING FORECAST PERIOD
4.2          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD (2023)
・     FIGURE 18        IN-VITRO PRODUCTION METHOD ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.3          MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
・     FIGURE 19        HUMAN SOURCE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
4.4          MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
・     FIGURE 20        GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5     MARKET OVERVIEW

5.1          INTRODUCTION
5.2          MARKET DYNAMICS
・     FIGURE 21        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1           DRIVERS
5.2.1.1          ADVANCEMENTS IN BIOTECHNOLOGY AND GENETIC ENGINEERING
5.2.1.2          INCREASING DEMAND FOR PERSONALIZED MEDICINE
5.2.1.3          GROWING PRODUCT PIPELINE OF MAB THERAPEUTICS
・     FIGURE 22        NUMBER OF ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN US/EU (2012−2023)
5.2.2           RESTRAINTS
5.2.2.1          STRINGENT REGULATORY APPROVAL PROCESS
5.2.2.2          HIGH COST OF MAB TREATMENTS
5.2.3           OPPORTUNITIES
5.2.3.1          INNOVATIVE THERAPEUTIC INDICATIONS
5.2.3.2          RISING TECHNOLOGICAL ADVANCEMENTS IN ANTIBODY ENGINEERING

5.2.4           CHALLENGES
5.2.4.1          RISING DEVELOPMENT & PRODUCTION COSTS
5.3          PORTER’S FIVE FORCES ANALYSIS
・     TABLE 1           MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1           THREAT OF NEW ENTRANTS
5.3.2           THREAT OF SUBSTITUTES
5.3.3           BARGAINING POWER OF SUPPLIERS
5.3.4           BARGAINING POWER OF BUYERS   60
5.3.5           INTENSITY OF COMPETITIVE RIVALRY
5.4          TECHNOLOGY ANALYSIS
5.4.1           CONVENTIONAL PRODUCTION OF MABS
5.4.2           TECHNOLOGICAL ADVANCEMENTS FOR MABS
・     TABLE 2           MONOCLONAL ANTIBODY THERAPEUTICS MARKET: TECHNOLOGY COMPARISON
5.5          VALUE CHAIN ANALYSIS
・     FIGURE 23        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN
5.6          PATENT ANALYSIS
5.6.1           METHODOLOGY
5.6.2           PATENTS FILED BY DOCUMENT TYPE, 2014–2023
・     TABLE 3           PATENTS FILED, 2014–2023
5.6.3           INNOVATION AND PATENT APPLICATIONS
・     FIGURE 24        TOTAL NUMBER OF PATENTS GRANTED, 2014–2023
5.6.4           TOP APPLICANTS
・     FIGURE 25        TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2023
・     FIGURE 26        REGIONAL ANALYSIS OF PATENTS GRANTED, 2014–2023
・     TABLE 4           TOP 10 PATENT OWNERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2013–2023
・     TABLE 5           PATENTS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2023−2024
5.7          KEY CONFERENCES & EVENTS
・     TABLE 6           MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024–2025)
5.8          INVESTMENT AND FUNDING SCENARIO
5.9          PIPELINE ANALYSIS
・     TABLE 7           MONOCLONAL ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE
5.10        SUPPLY CHAIN ANALYSIS
・     FIGURE 27        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
5.11        ECOSYSTEM ANALYSIS
・     FIGURE 28        MONOCLONAL ANTIBODY THERAPEUTICS ECOSYSTEM
5.11.1         MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
・     TABLE 8           MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
5.11.2         END USERS OF MONOCLONAL ANTIBODY THERAPEUTICS
・     TABLE 9           MONOCLONAL ANTIBODY THERAPEUTIC END USERS
5.11.3         REGULATORY BODIES FOR MONOCLONAL ANTIBODY THERAPEUTICS
・     TABLE 10          MONOCLONAL ANTIBODY THERAPEUTIC REGULATORY BODIES
5.12        REGULATORY LANDSCAPE
5.12.1         REGULATORY ANALYSIS
5.12.2         REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・     TABLE 11          NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・     TABLE 12          EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・     TABLE 13          ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・     TABLE 14          REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13        PRICING ANALYSIS
5.13.1         AVERAGE SELLING PRICE TREND OF KEY PLAYERS
・     TABLE 15          AVERAGE SELLING PRICE OF MONOCLONAL ANTIBODY THERAPEUTICS IN US
5.14        TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
・     FIGURE 29        TECHNOLOGICAL ADVANCEMENTS IN MONOCLONAL ANTIBODY PRODUCTION TO DRIVE MARKET GROWTH
5.15        KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1         KEY STAKEHOLDERS ON BUYING PROCESS
・     FIGURE 30        INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MABS AMONG TOP TWO END USERS
・     TABLE 16          INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS
5.15.2         BUYING CRITERIA FOR MONOCLONAL ANTIBODY THERAPEUTICS
・     FIGURE 31        KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES
・     TABLE 17          KEY BUYING CRITERIA FOR TOP TWO END USERS

6     MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD

6.1          INTRODUCTION
・     TABLE 18          MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
6.2          IN-VITRO PRODUCTION
6.2.1           HIGH SCALABILITY AND COST EFFICIENCY TO PROPEL MARKET
・     TABLE 19          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 20          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 21          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 22          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 23          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 24          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 25          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
6.3          IN-VIVO PRODUCTION
6.3.1           MINIMAL SIDE-EFFECTS TO SUPPORT MARKET GROWTH
・     TABLE 26          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 27          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 28          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 29          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 30          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 31          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 32          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)

7     MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

7.1          INTRODUCTION
・     TABLE 33          MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
7.2          INTRAVENOUS ROUTE OF ADMINISTRATION
7.2.1           DIRECT DELIVERY OF THERAPEUTIC DOSAGE FOR MULTIPLE INDICATIONS TO DRIVE MARKET
・     TABLE 34          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 35          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 36          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 37          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 38          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 39          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 40          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
7.3          SUBCUTANEOUS ROUTE OF ADMINISTRATION
7.3.1           ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO DRIVE MARKET
・     TABLE 41          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 42          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 43          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 44          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 45          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 46          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022−2029 USD MILLION)
・     TABLE 47          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
7.4          OTHER ROUTES OF ADMINISTRATION
・     TABLE 48          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 49          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 50          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 51          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 52          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 53          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 54          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTESC OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)

8     MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE

8.1          INTRODUCTION
・     TABLE 55          MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
8.2          HUMAN SOURCE
8.2.1           REDUCED IMMUNOGENICITY AND IMPROVED EFFICACY TO PROPEL MARKET
・     TABLE 56          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 57          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 58          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 59          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 60          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 61          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 62          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
8.3          HUMANIZED SOURCE
8.3.1           ABILITY TO ADJUST SPECIFICITY AND BIOLOGICAL FUNCTIONS TO DRIVE MARKET
・     TABLE 63          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 64          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 65          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 66          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 67          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 68          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 69          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
8.4          CHIMERIC SOURCE
8.4.1           UTILIZATION OF GENETIC ENGINEERING TECHNIQUES FOR MINIMIZED IMMUNOGENIC RESPONSES TO FUEL MARKET
・     TABLE 70          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 71          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 72          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 73          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 74          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 75          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 76          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
8.5          OTHER SOURCES
・     TABLE 77          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 78          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 79          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 80          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 81          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 82          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 83          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)

9     MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA

9.1          INTRODUCTION
・     TABLE 84          MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
9.2          INFLAMMATORY & AUTOIMMUNE DISORDERS
9.2.1           RISING DEMAND FOR TARGETED THERAPEUTICS TO DRIVE MARKET
・     TABLE 85          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 86          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 87          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 88          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 89          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 90          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 91          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
9.3          ONCOLOGY
9.3.1           GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET
・     TABLE 92          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 93          NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 94          EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 95          ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 96          LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 97          MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022−2029 (USD MILLION)
・     TABLE 98          GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022−2029 (USD MILLION)

9.4          HEMATOLOGY
9.4.1           RISING INCIDENCE OF THROMBOTIC DISORDERS TO SUPPORT MARKET GROWTH
・     TABLE 99          MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022−2029 (USD MILLION)
・     TABLE 100        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 101        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022−2029 (USD MILLION)
・     TABLE 102        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 103        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 104        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 105        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
9.5          OPHTHALMOLOGY
9.5.1           RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION TO BOOST DEMAND
・     TABLE 106        MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 107        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 108        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 109        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 110        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 111        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 112        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
9.6          OTHER THERAPY AREAS
・     TABLE 113        MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 114        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 115        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 116        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 117        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 118        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 119        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)

10  MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER

10.1        INTRODUCTION
・     TABLE 120        MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2        HOSPITALS
10.2.1         AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
・     TABLE 121        MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 122        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 123        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 124        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 125        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 126        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 127        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
10.3        LONG-TERM CARE FACILITIES
10.3.1         SPECIALIZED CARE AND CONTINUOUS MONITORING ADVANTAGES TO DRIVE MARKET
・     TABLE 128        MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 129        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 130        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 131        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 132        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 133        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 134        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
10.4        OTHER END USERS
・     TABLE 135        MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 136        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 137        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 138        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 139        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 140        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 141        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)

11  MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION

11.1        INTRODUCTION
・     TABLE 142        MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
11.2        NORTH AMERICA
・     FIGURE 32        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT
・     TABLE 143        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 144        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 145        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 146        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 147        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 148        NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.1         NORTH AMERICA: RECESSION IMPACT
11.2.2         US
11.2.2.1        RISING REGULATORY APPROVALS FOR PRODUCT COMMERCIALIZATION TO PROPEL MARKET
・     TABLE 149        PRODUCT APPROVALS FOR MAB THERAPEUTICS BY US FDA
・     TABLE 150        US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 151        US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 152        US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 153        US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 154        US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.3         CANADA
11.2.3.1        RISING INVESTMENTS IN ANTIBODY RESEARCH TO SUPPORT MARKET GROWTH
・     TABLE 155        CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 156        CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 157        CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 158        CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 159        CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3        EUROPE
・     FIGURE 33        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT
・     TABLE 160        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 161        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 162        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 163        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 164        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 165        EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.1         EUROPE: RECESSION IMPACT
11.3.2         GERMANY
11.3.2.1        RISING NUMBER OF CLINICAL TRIALS FOR MAB THERAPEUTICS TO DRIVE MARKET
・     TABLE 166        GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 167        GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 168        GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 169        GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 170        GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.3         UK
11.3.3.1        INCREASING R&D INITIATIVES BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO SUPPORT MARKET GROWTH
・     TABLE 171        UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
・     TABLE 172        UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 173        UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 174        UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 175        UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 176        UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.4         FRANCE
11.3.4.1        FAVORABLE REIMBURSEMENT POLICIES FOR THERAPEUTIC TREATMENTS TO PROPEL MARKET
・     TABLE 177        FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 178        FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 179        FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 180        FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 181        FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.5         ITALY
11.3.5.1        GROWTH IN LIFE SCIENCES INDUSTRY TO BOOST DEMAND
・     TABLE 182        ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 183        ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 184        ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 185        ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 186        ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.6         SPAIN
11.3.6.1        GROWING FOCUS ON RESEARCH FOR BIOMATERIAL DEVELOPMENT TO DRIVE MARKET
・     TABLE 187        SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 188        SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 189        SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 190        SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 191        SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.7         TURKEY
11.3.7.1        RISING INVESTMENTS IN R&D FOR HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
・     TABLE 192        TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 193        TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 194        TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 195        TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 196        TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.8         REST OF EUROPE
・     TABLE 197        REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 198        REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 199        REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 200        REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 201        REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4        ASIA PACIFIC
・     TABLE 202        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 203        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 204        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 205        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 206        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 207        ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.1         ASIA PACIFIC: RECESSION IMPACT
11.4.2         CHINA
11.4.2.1        GROWING PREFERENCE FOR PRECISION MEDICINES TO PROPEL MARKET
・     TABLE 208        CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 209        CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 210        CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 211        CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 212        CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.3         JAPAN
11.4.3.1        AVAILABILITY OF HEALTHCARE INSURANCE AND FAVORABLE REGULATORY ENVIRONMENT TO PROPEL MARKET
・     TABLE 213        JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 214        JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 215        JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 216        JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 217        JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)

11.4.4         INDIA
11.4.4.1        INCREASING INCIDENCE OF CHRONIC DISEASES AND HIGH GROWTH IN PHARMA R&D TO FUEL MARKET
・     TABLE 218        INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 219        INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 220        INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 221        INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 222        INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.5         SOUTH KOREA
11.4.5.1        STRATEGIC INITIATIVES BY KEY PLAYERS TO SUPPORT MARKET GROWTH
・     TABLE 223        SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 224        SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 225        SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 226        SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 227        SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.6         INDONESIA
11.4.6.1        FUNDING INITIATIVES AND KEY PRODUCT LAUNCHES TO SUPPORT MARKET GROWTH
・     TABLE 228        INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 229        INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 230        INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 231        INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 232        INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.7         MALAYSIA
11.4.7.1        INCREASING FOCUS ON GOVERNMENT-FUNDED INITIATIVES FOR MANAGEMENT OF CHRONIC AILMENTS TO SUPPORT MARKET GROWTH
・     TABLE 233        MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 234        MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 235        MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 236        MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 237        MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.8         REST OF ASIA PACIFIC
・     TABLE 238        REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 239        REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 240        REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)  211
・     TABLE 241        REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 242        REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5        LATIN AMERICA
・     TABLE 243        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 244        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 245        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 246        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 247        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 248        LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.1         LATIN AMERICA: RECESSION IMPACT
11.5.2         BRAZIL
11.5.2.1        INCREASING INCIDENCE OF CHRONIC & INFECTIOUS DISEASES TO DRIVE MARKET
・     TABLE 249        BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 250        BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 251        BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 252        BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 253        BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.3         REST OF LATIN AMERICA
・     TABLE 254        REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 255        REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 256        REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)  219
・     TABLE 257        REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 258        REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6        MIDDLE EAST
・     TABLE 259        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
・     TABLE 260        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 261        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 262        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 263        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 264        MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.1         MIDDLE EAST: RECESSION IMPACT
11.6.2         GCC COUNTRIES
・     TABLE 265        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
・     TABLE 266        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 267        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 268        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 269        GCC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 270        GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2.1        SAUDI ARABIA
11.6.2.1.1        RISING PREVALENCE OF CVD TO SUPPORT MARKET GROWTH
・     TABLE 271        SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 272        SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 273        SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 274        SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 275        SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2.2        UNITED ARAB EMIRATES
11.6.2.2.1        RISING PREVALENCE OF DIABETES TO BOOST DEMAND
・     TABLE 276        UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 277        UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 278        UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)  229
・     TABLE 279        UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 280        UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2.3        OTHER GCC COUNTRIES
・     TABLE 281        OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 282        OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 283        OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)  231
・     TABLE 284        OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 285        OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.3         REST OF MIDDLE EAST
・     TABLE 286        REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 287        REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 288        REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)  234
・     TABLE 289        REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・     TABLE 290        REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.7        AFRICA
11.7.1         HIGH INVESTMENTS IN HEALTHCARE R&D TO SUPPORT MARKET GROWTH
・     TABLE 291        AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・     TABLE 292        AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・     TABLE 293        AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・     TABLE 294        AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)  237
・     TABLE 295        AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.7.2         AFRICA: RECESSION IMPACT

12  COMPETITIVE LANDSCAPE

12.1        INTRODUCTION
12.2        KEY PLAYER STRATEGIES/RIGHT TO WIN
・     FIGURE 34        STRATEGIES ADOPTED BY KEY PLAYERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET
12.3        REVENUE SHARE ANALYSIS
・     FIGURE 35        REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020−2023)
12.4        MARKET SHARE ANALYSIS
・     FIGURE 36        MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
・     TABLE 296        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DEGREE OF COMPETITION
12.5        COMPANY EVALUATION MATRIX: KEY PLAYERS
12.5.1         STARS
12.5.2         EMERGING LEADERS
12.5.3         PERVASIVE PLAYERS
12.5.4         PARTICIPANTS
・     FIGURE 37        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2023)
12.5.5         COMPANY FOOTPRINT
・     FIGURE 38        COMPANY FOOTPRINT (15 COMPANIES)
12.5.5.1        TYPE FOOTPRINT
・     TABLE 297        TYPE FOOTPRINT (15 COMPANIES)
12.5.5.2        REGIONAL FOOTPRINT
・     TABLE 298        REGIONAL FOOTPRINT (15 COMPANIES)
12.6        COMPANY EVALUATION MATRIX: STARTUP/SME PLAYERS
12.6.1         PROGRESSIVE COMPANIES
12.6.2         DYNAMIC COMPANIES
12.6.3         RESPONSIVE COMPANIES
12.6.4         STARTING BLOCKS
・     FIGURE 39        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2023)
12.7        COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
・     TABLE 299        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
・     TABLE 300        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
12.8        VALUATION AND FINANCIAL METRICS OF MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
・     FIGURE 40        EV/EBITDA OF KEY VENDORS
・     FIGURE 41        YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
12.9        BRAND/PRODUCT COMPARATIVE ANALYSIS
12.9.1         BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE
・     FIGURE 42        BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE
12.9.1.1        F. HOFFMANN-LA ROCHE LTD.
12.9.1.2        JOHNSON & JOHNSON SERVICES, INC.
12.9.1.3        MERCK & CO., INC.
12.9.1.4        ABBVIE INC.
12.9.1.5        SANOFI
12.9.2         BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE
・     FIGURE 43        BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE
12.9.2.1        ASTRAZENECA
12.9.2.2        BRISTOL MYERS SQUIBB COMPANY
12.9.2.3        NOVARTIS AG
12.10      COMPETITIVE SCENARIO
12.10.1       PRODUCT LAUNCHES & APPROVALS
・     TABLE 301        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2021−JANUARY 2024)
12.10.2       DEALS
・     TABLE 302        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DEALS (JANUARY 2021−JANUARY 2024)
12.10.3       OTHER DEVELOPMENTS
・     TABLE 303        MONOCLONAL ANTIBODY THERAPEUTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2021−JANUARY 2024)

13  COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS/SERVICES OFFERED, RECENT DEVELOPMENTS & MNM VIEW)*
13.1        KEY PLAYERS
13.1.1         F. HOFFMANN-LA ROCHE LTD.
・     TABLE 304        F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
・     FIGURE 44        F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
・     TABLE 305        F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
・     TABLE 306        F. HOFFMAN LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
・     TABLE 307        F. HOFFMAN LA ROCHE LTD.: DEALS
13.1.2         JOHNSON & JOHNSON SERVICES, INC.
・     TABLE 308        JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
・     FIGURE 45        JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2022)
・     TABLE 309        JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES OFFERED
・     TABLE 310        JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS
13.1.3         MERCK & CO., INC.
・     TABLE 311        MERCK & CO., INC.: COMPANY OVERVIEW
・     FIGURE 46        MERCK & CO., INC COMPANY SNAPSHOT (2022)
・     TABLE 312        MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED
・     TABLE 313        MERCK & CO., INC.: PRODUCT APPROVALS
13.1.4         ABBVIE INC.
・     TABLE 314        ABBVIE INC.: COMPANY OVERVIEW
・     FIGURE 47        ABBVIE INC.: COMPANY SNAPSHOT (2022)
・     TABLE 315        ABBVIE INC.: PRODUCTS /SERVICES OFFERED
・     TABLE 316        ABBVIE INC.: PRODUCT APPROVALS   280
・     TABLE 317        ABBVIE INC.: DEALS
13.1.5         BRISTOL-MYERS SQUIBB COMPANY  282
・     TABLE 318        BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
・     FIGURE 48        BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)
・     TABLE 319        BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED
・     TABLE 320        BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS
・     TABLE 321        BRISTOL-MYERS SQUIBB COMPANY: DEALS
・     TABLE 322        BRISTOL-MYERS SQUIBB COMPANY: OTHER DEVELOPMENTS
13.1.6         ASTRAZENECA
・     TABLE 323        ASTRAZENECA: COMPANY OVERVIEW
・     FIGURE 49        ASTRAZENECA: COMPANY SNAPSHOT (2022)
・     TABLE 324        ASTRAZENECA: PRODUCTS/SERVICES OFFERED
・     TABLE 325        ASTRAZENECA: PRODUCT APPROVALS   290
・     TABLE 326        ASTRAZENECA: DEALS
13.1.7         SANOFI
・     TABLE 327        SANOFI: COMPANY OVERVIEW
・     FIGURE 50        SANOFI: COMPANY SNAPSHOT (2022)
・     TABLE 328        SANOFI: PRODUCTS/SERVICES OFFERED
・     TABLE 329        SANOFI: PRODUCT APPROVALS
・     TABLE 330        SANOFI: DEALS
13.1.8         NOVARTIS AG
・     TABLE 331        NOVARTIS AG: COMPANY OVERVIEW
・     FIGURE 51        NOVARTIS AG: COMPANY SNAPSHOT (2022)
・     TABLE 332        NOVARTIS AG: PRODUCTS/SERVICES OFFERED
・     TABLE 333        NOVARTIS AG: PRODUCT APPROVALS
・     TABLE 334        NOVARTIS AG: DEALS
・     TABLE 335        NOVARTIS AG: OTHER DEVELOPMENTS
13.1.9         AMGEN INC.
・     TABLE 336        AMGEN INC.: COMPANY OVERVIEW    304
・     FIGURE 52        AMGEN INC.: COMPANY SNAPSHOT (2022)
・     TABLE 337        AMGEN INC.: PRODUCTS/SERVICES OFFERED
・     TABLE 338        AMGEN INC.: PRODUCT APPROVALS
・     TABLE 339        AMGEN INC.: DEALS
・     TABLE 340        AMGEN INC.: EXPANSIONS
13.1.10       TAKEDA PHARMACEUTICAL COMPANY LIMITED
・     TABLE 341        TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
・     FIGURE 53        TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
・     TABLE 342        TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS/SERVICES OFFERED
・     TABLE 343        TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
13.1.11       GSK PLC.
・     TABLE 344        GSK PLC.: COMPANY OVERVIEW    312
・     FIGURE 54        GSK PLC.: COMPANY SNAPSHOT (2022)
・     TABLE 345        GSK PLC.: PRODUCTS/SERVICES OFFERED
・     TABLE 346        GSK PLC.: PRODUCT APPROVALS   314
・     TABLE 347        GSK PLC.: DEALS
・     TABLE 348        GSK PLC.: OTHER DEVELOPMENTS   316

13.1.12       ELI LILLY AND COMPANY
・     TABLE 349        ELI LILLY AND COMPANY: COMPANY OVERVIEW
・     FIGURE 55        ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
・     TABLE 350        ELI LILLY AND COMPANY: PRODUCTS/SERVICES OFFERED
・     TABLE 351        ELI LILLY AND COMPANY: PRODUCT APPROVALS
・     TABLE 352        ELI LILLY AND COMPANY: DEALS   320
・     TABLE 353        ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
13.1.13       REGENERON PHARMACEUTICALS INC.
・     TABLE 354        REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
・     FIGURE 56        REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2022)
・     TABLE 355        REGENERON PHARMACEUTICALS INC.: PRODUCTS/SERVICES OFFERED
・     TABLE 356        REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS
・     TABLE 357        REGENERON PHARMACEUTICALS INC.: DEALS
13.1.14       BIOGEN
・     TABLE 358        BIOGEN: COMPANY OVERVIEW
・     FIGURE 57        BIOGEN: COMPANY SNAPSHOT (2022)
・     TABLE 359        BIOGEN: PRODUCTS/SERVICES OFFERED
・     TABLE 360        BIOGEN: PRODUCT APPROVALS
・     TABLE 361        BIOGEN: DEALS
13.1.15       UCB S.A.
・     TABLE 362        UCB S.A.: COMPANY OVERVIEW
・     FIGURE 58        UCB S.A.: COMPANY SNAPSHOT (2022)
・     TABLE 363        UCB S.A.: PRODUCTS/SERVICES OFFERED
・     TABLE 364        UCB S.A.: DEALS
・     TABLE 365        UCB S.A.: PRODUCT APPROVALS   333
13.2        OTHER PLAYERS
13.2.1         BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.2.2         Y-MABS THERAPEUTICS, INC.
13.2.3         TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.2.4         MERCK KGAA
13.2.5         KYOWA KIRIN CO., LTD.
13.2.6         SWEDISH ORPHAN BIOVITRUM AB   339
13.2.7         UNITED THERAPEUTICS CORPORATION
13.2.8         THERATECHNOLOGIES INC.
13.2.9         INCYTE
13.2.10       SUN PHARMACEUTICAL INDUSTRIES, INC.
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS/SERVICES OFFERED, RECENT DEVELOPMENTS & MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

14  APPENDIX

△ 一番上に戻る